Communiqués Acura Pharmaceuticals, Inc.

Actions

ACUR

US00509L8028

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 16:49:12 20/04/2026			Varia. 5j.	Varia. 1 janv.
0,000100 ^USD	-80,00%		-50,00%	-80,00%

30/05/25	Acura Pharmaceuticals, Inc. annonce un accord de licence, de développement et de commercialisation avec AD Pharma	CI
21/05/25	Acura Pharmaceuticals, Inc. et Abuse Deterrent Pharma, LLC annoncent une deuxième réunion avec la Food and Drug Administration américaine	CI

Communiqués

16/12/24	Acura Pharmaceuticals : Financial Obligation Form 8 K	PU
26/07/24	Acura Pharmaceuticals : New Financial Obligation Form 8 K	PU
26/03/24	Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	PU
21/12/23	Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K	PU
06/12/23	Acura Pharmaceuticals : New Financial Obligation - Form 8-K	PU
16/08/23	Acura Pharmaceuticals : Termination of Material Agreement - Form 8-K	PU
28/06/23	Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	PU
20/03/23	ACURA PHARMACEUTICALS, INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)	AQ
22/02/23	ACURA PHARMACEUTICALS, INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)	AQ
13/02/23	ACURA PHARMACEUTICALS, INC : Other Events (form 8-K)	AQ
02/02/23	ACURA PHARMACEUTICALS, INC : Other Events (form 8-K)	AQ
20/01/23	ACURA PHARMACEUTICALS, INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)	AQ
27/12/22	ACURA PHARMACEUTICALS, INC : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
14/11/22	ACURA PHARMACEUTICALS, INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)	AQ
17/10/22	Acura Pharmaceuticals : NEGOTIABLE PROMISSORY NOTE - Form 8-K	PU
17/10/22	ACURA PHARMACEUTICALS, INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
26/09/22	Acura Pharmaceuticals : NEGOTIABLE PROMISSORY NOTE - Form 8-K	PU
26/09/22	ACURA PHARMACEUTICALS, INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
26/08/22	ACURA PHARMACEUTICALS, INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
28/07/22	ACURA PHARMACEUTICALS, INC : Other Events (form 8-K)	AQ
19/07/22	ACURA PHARMACEUTICALS, INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
14/07/22	ACURA PHARMACEUTICALS, INC : Other Events (form 8-K)	AQ
11/07/22	ACURA PHARMACEUTICALS, INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
13/06/22	ACURA PHARMACEUTICALS, INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
23/05/22	Acura Pharmaceuticals : NEGOTIABLE PROMISSORY NOTE - Form 8-K	PU